|
Aurobindo has received USFDA
approval for Lamivudine, a key ARV in the
treatment of AIDS, enabling the Company to
participate in PEPFAR (President’s Emergency
Plan for Aids Relief), an initiative by US
Government. |
|
The Company manufactures both API
and formulation for Lamivudine. Aurobindo is
participating in PEPFAR programme wherein around
US $ 15 billions are earmarked for this
five-year programme including around US $ 1
billion per year for medicines. Approval for
product, plant and bio-equivalence for API and
formulation with US FDA is an important
qualifying criteria to participate in the
programme. |
|
This is a very significant
landmark in penetrating the global ARV business.
The Company has already filed several
applications in the ARV segment with US FDA. |
|
Aurobindo is fully vertically
integrated in manufacturing APIs and
Formulations across most ARVs (NRTIs, NNRTIs and
PIs) for the PEPFAR programme and hence well
positioned as a very competitive player.
|
|
This development can help
Aurobindo make a significant leap in the value
chain from APIs to formulations in global ARV
segment. |
|
|
|
About Aurobindo Pharma Limited |
|
Aurobindo Pharma Limited
headquartered at Hyderabad, India manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The Company’s robust
product portfolio is spread over 6 major
therapeutic/product areas encompassing
(Antibiotics, Anti-Retrovirals, CVS, CNS,
Gastroenterologicals, and Anti-Allergics) with
around 65 APIs in the non-antibiotics and over
55 APIs in the antibiotic segment. The Company
is marketing these products globally, in over
100 countries. |
PRESS
ROOM
